NASDAQ:ATAI XETRA:9VC

AtaiBeckley Inc.

Market:

NASDAQ

Price

7.21 USD

Day Change

0.42%

Market Cap:

$2.67 b

52 weeks high

7.22

52 weeks low

3.27

Filter by article type

Viewing results 1-25 of 143

News

AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics

3 weeks ago

AtaiBeckley bets on next-gen psychedelic medicines to transform mental health

3 weeks ago

News

Eli Lilly's $3.8bn psychedelics bet is built on British science

3 weeks ago

News

Nasdaq slides as chip selloff drags Wall Street lower

3 weeks, 1 day ago

News

AtaiBeckley to be acquired by Eli Lilly in deal valued at up to $3.8 billion

3 weeks, 1 day ago

News

Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies

3 weeks, 2 days ago

News

Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says

3 weeks, 4 days ago

News

AtaiBeckley set to unlock value from positive depression therapy trial results, says Jefferies

1 month ago

News

AtaiBeckley completes dosing in Phase 2b depression trial, expects topline data in Q4

on 6/7/26

News

AtaiBeckley to join Russell 2000 and Russell 3000 indexes following annual reconstitution

on 25/6/26

News

AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy’ rating

on 4/6/26

News

Nasdaq hits record high as S&P 500 also climbs on US-Iran deal hopes

on 28/5/26

News

AtaiBeckley launches mental health patient impact grant program

on 28/5/26

News

AtaiBeckley to participate in multiple June investor conferences

on 27/5/26

News

AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says

on 13/5/26

News

AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances

on 12/5/26

News

S&P 500 and Nasdaq close at fresh records as tech leads quiet advance

on 27/4/26

News

AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials

on 27/4/26

News

Psychedelics stocks rise after Trump order expands research, access pathways

on 20/4/26

News

Johnson & Johnson’s Spravato sales growth signals upside for psychedelics peers

on 14/4/26

News

Nasdaq leads strong finish as markets cheer temporary US-Iran ceasefire

on 8/4/26

News

AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003

on 8/4/26

News

AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts

on 27/3/26

News

Nasdaq closes down as investors stay cautious on geopolitics

on 24/3/26

News

AtaiBeckley added to major US indices, increasing reach among passive investors

on 24/3/26